stoxline Quote Chart Rank Option Currency Glossary
Viking Therapeutics, Inc. (VKTX)
59.61  0.98 (1.67%)    07-12 12:15
Open: 58.82
High: 59.73
Volume: 1,026,183
Pre. Close: 58.63
Low: 57.51
Market Cap: 6,573(M)
Technical analysis
2024-07-12 11:53:16 AM
Short term     
Mid term     
Targets 6-month :  70.34 1-year :  82.16
Resists First :  60.22 Second :  70.34
Pivot price 52.89
Supports First :  51.5 Second :  46.11
MAs MA(5) :  56.2 MA(20) :  52.53
MA(100) :  65.44 MA(250) :  35.66
MACD MACD :  -0.7 Signal :  -2.2
%K %D K(14,3) :  92 D(3) :  80.6
RSI RSI(14): 57.9
52-week High :  99.41 Low :  8.27
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VKTX ] has closed below upper band by 4.4%. Bollinger Bands are 52% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 60.3 - 60.53 60.53 - 60.76
Low: 55.83 - 56.1 56.1 - 56.37
Close: 58.19 - 58.61 58.61 - 59.03
Company Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Headline News

Thu, 11 Jul 2024
Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down to $57.99 - MarketBeat

Thu, 11 Jul 2024
Jennison Associates LLC Acquires New Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World

Thu, 11 Jul 2024
S&P 500 Futures Fall in Premarket Trading; Delta Air Lines, Viking Therapeutics Lag - Barron's

Tue, 09 Jul 2024
Viking Therapeutics: Potential Winner In Competitive Obesity Drug Race (NASDAQ:VKTX) - Seeking Alpha

Thu, 27 Jun 2024
What Makes Viking Therapeutics, Inc. (VKTX) One of the Best Healthcare Stocks to Buy Under $50? - Yahoo Finance

Mon, 24 Jun 2024
Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 110 (M)
Shares Float 104 (M)
Held by Insiders 6 (%)
Held by Institutions 75.2 (%)
Shares Short 12,670 (K)
Shares Short P.Month 12,170 (K)
Stock Financials
EPS -0.93
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.47
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -12.8 %
Return on Equity (ttm) -17.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -55 (M)
Levered Free Cash Flow -22 (M)
Stock Valuations
PE Ratio -64.4
PEG Ratio -1.2
Price to Book value 6.99
Price to Sales 0
Price to Cash Flow -119.07
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android